Supply Chain Structural Change: Pharmaceutical Industry Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

Operating Margin: Declined from 18% (2018) to 12% (2023) due to rising API procurement costs (Exhibit 2).
Inventory Turnover: Stagnated at 4.2x, significantly below the industry benchmark of 6.5x (Exhibit 3).
Working Capital: $450M tied up in safety stock across three regional distribution centers (Paragraph 14).

Operational Facts

Manufacturing Footprint: Four centralized plants in Europe; distribution via third-party logistics providers (3PLs) (Paragraph 8).
Lead Times: Average order-to-delivery time is 45 days, with 12% variance (Exhibit 5).
Regulatory Environment: Stricter serialization requirements (DSCSA compliance) effective Q4 2024 (Paragraph 22).

Stakeholder Positions

CEO (Marcus Thorne): Focused on short-term margin recovery and shareholder dividends.
Head of Supply Chain (Sarah Jenkins): Advocates for regionalization to mitigate lead-time volatility.
CFO (David Wu): Skeptical of capital expenditure required for regional distribution centers.

Information Gaps

Specific cost-benefit analysis for decentralized warehousing vs. centralized automation.
Detailed breakdown of logistics costs by region.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

How should the company reconfigure its supply chain to restore margins while meeting upcoming regulatory compliance, given the current 45-day lead time failure rate?

Structural Analysis

Value Chain: The current centralized model creates a single point of failure in Europe. High inventory levels are a hedge against poor forecast accuracy, not a strategic choice.
Porter Five Forces: Supplier power is high (API concentration). Buyer power (hospital groups) is increasing due to consolidation.

Strategic Options

Option 1: Regional Hub-and-Spoke. Move final packaging closer to markets. Requires $120M CAPEX. Reduces lead times to 15 days.
Option 2: Digital Twin Integration. Upgrade forecasting software to reduce safety stock. Low CAPEX ($25M). Does not solve physical lead time issues.
Option 3: Vertical Integration. Acquire a key API supplier. High risk, high cost. Provides long-term margin protection.

Preliminary Recommendation

Pursue Option 1. The structural inability to meet delivery windows is a greater threat to market share than the upfront capital cost. Option 2 is a temporary patch; Option 3 is a distraction from core operational failures.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

Month 1-3: Vendor selection for regional facility automation.
Month 4-9: Pilot implementation in the North American market.
Month 10-18: Full transition to regional model, decommissioning redundant centralized capacity.

Key Constraints

Regulatory Approval: New sites require local health authority certification (FDA/EMA).
Talent Scarcity: Lack of local expertise to run sophisticated serialization equipment in smaller regional hubs.

Risk-Adjusted Implementation

Maintain 15% extra safety stock during the 18-month transition phase. If pilot performance in North America misses 90% service level, pause global rollout to reassess facility design.

4. Executive Review and BLUF (Executive Critic)

BLUF

The company must transition to a regionalized supply chain immediately. The current reliance on centralized European production is a legacy model that fails to address modern inventory volatility and regulatory requirements. While the CFO is correct to worry about capital expenditure, the cost of inaction—market share erosion due to poor service levels—is higher. The board should approve the $120M allocation for regional hubs, contingent upon a phased, regional-by-regional rollout that prioritizes the North American market first to validate ROI.

Dangerous Assumption

The analysis assumes that regionalization will automatically solve the service level issues. It ignores the fact that regionalizing without fixing underlying forecast accuracy will simply move the inventory problem, not solve it.

Unaddressed Risks

Operational Risk: The organizational culture is built on centralized control. Moving to regional hubs will require a massive shift in decision-making authority that the current management team may lack.
Regulatory Risk: The strategy assumes serialization compliance can be handled locally; failure to standardize this process across regions could lead to massive compliance fines.

Unconsidered Alternative

Outsource the entire logistics and distribution network to a specialized global 4PL. This would convert fixed costs to variable costs and allow the company to focus exclusively on manufacturing, avoiding the heavy CAPEX of regional hubs.